Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map
Zolopa C., Høj S., Minoyan N., Bruneau J., Makarenko I., Larney S., Addiction, 2022
Substance
Opioids
Publications
Profiles of Patients with Opioid Use Disorders Presenting a History of Suicidal Ideations and Attempts
Archambault L., Jutras-Aswad D., Touré E.H., Artunduaga A.C., Roy S., Barbeau D., Perreault M., Psychiatric Quarterly, 2022
Interventions to Reduce Opioid Use in Youth At-Risk and in Treatment for Substance Use Disorders: A Scoping Review
Nairn SA, Audet M, Stewart SH, Hawke LD, Isaacs JY, Henderson J, Saah R, Knight R, Fast D, Khan F, Lam A, Conrod P., Canadian Journal of Psychiatry, 2022
A scoping review of opioid harm reduction interventions for equity-deserving populations
Milaney K, Haines-Saah R, Farkas B, Egunsola O, Mastikhina L, Brown S, Lorenzetti D, Hansen B, McBrien K, Rittenbach K, Hill L, O’Gorman C, Doig C, Cabaj J, Stokvis C, Clement F. , Lancet Reg Health Am. 2022
Problematic Opioid Use: A Scoping Literature Review of Profiles
Archambault L., Bertrand K., Perreault M., Substance Abuse: Treatment, Prevention, and Policy, 2022
Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids
Juwono S, Milloy MJ, Choi J, Fairbairn N, Nolan S, Socías ME., AIDS. 2022
Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report
MacAusland-Berg J, Wiebe A, Marwah R, Halpape K., Can J Pain. 2022
The practice and embodiment of “goofballs”: A qualitative study exploring the co-injection of methamphetamines and opioids
Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, McNeil R., Int J Drug Policy. 2022
Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada
Pilarinos A, Kwa Y, Joe R, Thulien M, Buxton JA, DeBeck K, Fast D., Int J Drug Policy. 2022
Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial
Socias ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, Bruneau J, Rehm J, Wild TC, Bozinoff N, Hassan A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.,
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial
Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Am J Psychiatry. 2022
Challenges and opportunities for further research involving the cannabis-to-opioid use transition
Bahji A, Milloy MJ, Bach P, Sociás ME., Addiction. 2022
Challenges and opportunities for further research involving the cannabis-to-opioid use transition
Bahji A, Milloy MJ, Bach P, Sociás ME. Addiction. 2022
Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial
Socias ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, Bruneau J, Rehm J, Wild TC, Bozinoff N, Hassan A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Addiction. 2022
The North American opioid crisis: how effective are supervised consumption sites?
Kennedy MC, Karamouzian M, Marshall BDL., Lancet. 2022
Using synthetic controls to estimate the population-level effects of Ontario’s recently implemented overdose prevention sites and consumption and treatment services
Dimitra Panagiotoglou, Jihoon Lim, International Journal of Drug Policy, 2022
Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study
Karamouzian M, Buxton JA, Hategeka C, Nosova E, Hayashi K, Milloy MJ, Kerr T., Int J Drug Policy. 2022
Development and pilot evaluation of an educational session to support sparing opioid prescriptions to opioid naïve patients in a Canadian primary care setting
Narayan S, Rizzardo S, Hamilton MA, Cooper I, Maclure M, McCracken RK, Klimas J., Fam Pract. 2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino JP, Bahji A, Gómez O, Sofuoglu M., Drug Alcohol Depend. 2022
Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada
Cui Z, Bach P, Ti L, Hayashi K, Morgan J, Milloy MJ, Kerr T., Int J Drug Policy. 2022
Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study
Kennedy MC, Crabtree A, Nolan S, Mok WY, Cui Z, Chong M, Slaunwhite A, Ti L., PLoS Med. 2022
Cases: Multiorgan failure in a 38-year-old man with recent consumption of kratom, an atypical opioid
Bahji A, Socías ME, Bach P, Psychiatry Res Case Rep, 2022.
Letter to the Editor: Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?
De Aquino JP, Bahji A, D’Souza DC., Cannabis Cannabinoid Res. 2022
The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs
Lake S, Kerr T, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ., Cannabis Cannabinoid Res. 2023
Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada
Pilarinos A, Kwa Y, Joe R, Dong H, Grant C, Fast D, Buxton JA, DeBeck K., Can J Psychiatry. 2023
Examining fentanyl and its analogues in the unregulated drug supply of British Columbia, Canada using drug checking technologies
Crepeault H, Socias ME, Tobias S, Lysyshyn M, Custance A, Shapiro A, Ti L. , Drug Alcohol Rev. 2023
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17
Larney S., Jones N.R., Hickman M., Nielsen S., Ali R., Degenhardt L., Addiction, 2023
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
Lim J., Farhat I., Douros A., Panagiotoglou D., PLoS ONE, 2022
Using photovoice to understand experiences of opioid use among sexual and gender minority youth in Vancouver, Canada
Goodyear T, Ferlatte O, Fast D, Salway T, Jenkins E, Robinson S, Knight R., Cult Health Sex. 2023
People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile-based approach to care
Archambault L., Bertrand K., Jutras-Aswad D., Monson E., Touré E.H., Perreault M., Drug and Alcohol Review, 2023
Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes
Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T., CMAJ. 2023
People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile-based approach to care
Archambault L., Bertrand K., Jutras-Aswad D., Monson E., Touré E.H., Perreault M., Drug and Alcohol Review, 2023
Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments
Stone KD, Scott K, Holroyd BR, Lang E, Yee K, Taghizadeh N, Deol J, Dong K, Fanaeian J, Ghosh M, Low K, Ross M, Tanguay R, Faris P, Day N, McLane P., CJEM. 2023
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder
Enns B, Krebs E, Whitehurst DGT, Jutras-Aswad D, Le Foll B, Socias ME, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Drug Alcohol Depend. 2023
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial
Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Cheol Choi J, Yin Mok W, Eugenia Socias M; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.,
Development of a neural network model to predict the presence of fentanyl in community drug samples
Ti L, Grant CJ, Tobias S, Hore DK, Laing R, Marshall BDL., PLoS One. 2023
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis
Eugenia Socias M, Choi JC, Fairbairn N, Johnson C, Wilson D, Debeck K, Brar R, Hayashi K, Int J Drug Policy. 2023
Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder
Nickols JER, Dursun SM, Taylor AMW., Neuropharmacology. 2023
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada
Whitehurst DGT, Mah C, Krebs E, Enns B, Socias ME, Jutras-Aswad D, Le Foll B, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Qual Life Res. 2023
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17
Larney S., Jones N.R., Hickman M., Nielsen S., Ali R., Degenhardt L., Addiction, 2023
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Am J Addict. 2023
Longitudinal latent polysubstance use patterns among a cohort of people who use opioids in Vancouver, Canada
Karamouzian M, Cui Z, Hayashi K, DeBeck K, Milloy MJ, Buxton JA, Kerr T., Drug Alcohol Rev. 2023
Cannabis use to manage opioid cravings among people who use unregulated opioids during a drug toxicity crisis
Reddon H, Lake S, Socias ME, Hayashi K, DeBeck K, Walsh Z, Milloy MJ., Int J Drug Policy. 2023
Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis
Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, Bonn M, Touesnard N, Henderson N, Bowles J, Boyd J, Brunelle C, Eeuwes J, Fikowski J, Gomes T, Guta A, Hyshka E, Ivsins A, Kennedy MC, Laurence G, Martignetti L, Nafeh F, Salters K, Tu D, Strike C, Pauly B, Werb D., Int J Drug Policy. 2023
Implications of Cannabis Legalization on Substance-Related Benefits and Harms for People Who Use Opioids: A Canadian Perspective
Bahji A, Socias ME, Bach P, Milloy MJ., Cannabis Cannabinoid Res. 2023
Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders
Martin N.K., Beletsky L., Linas B.P., Bayoumi A., Pollack H., Larney S., Journal of Urban Health, 2023
What impact did the COVID-19 pandemic have on the variability of fentanyl concentrations in the Vancouver, Canada illicit drug supply? An interrupted time-series analysis
Tobias S, Grant CJ, Laing R, Lysyshyn M, Buxton JA, Tupper KW, Wood E, Ti L, BMJ Public Health, 2023.
Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies
Bhuiyan I, Tobias S, Ti L., Am J Drug Alcohol Abuse. 2023
Evaluation of audit and feedback to family physicians on prescribing of opioid analgesics to opioid-naïve patients: A pragmatic randomized delay trial
McCracken RK, Narayan S, Maclure M, Cooper I, Cui Z, Cullen W, Dormuth C, Hamilton MA, Nolan S, Singer J, Socías ME, Wong S, Klimas J., Contemp Clin Trials. 2023
Correlates of nonfatal overdose among treatment-seeking individuals with non-heroin opioid use disorder: Findings from a pragmatic, pan-Canadian, randomized control trial
Crepeault H, Ti L, Jutras-Aswad D, Wood E, Le Foll B, Lim R, Bach P, Brar R, Socias ME., J Subst Use Addict Treat. 2023
Trajectories of opioid consumption as predictors of patient-reported outcomes among individuals attending multidisciplinary pain treatment clinics
Angarita-Fonseca A, Lacasse A, Choinière M, Kaboré JL, Sylvestre MP, Dinkou GDT, Bruneau J, Martel MO, Hovey R, Motulsky A, Rahme E, Pagé MG., Pharmacoepidemiology and Drug Safety, 2024
Fentanyl Concentration in Drug Checking Samples and Risk of Overdose Death in Vancouver, Canada
Kennedy MC, Dong H, Tobias S, Buxton JA, Lysyshyn M, Tupper KW, Ti L., Am J Prev Med. 2024
Trajectories of opioid consumption as predictors of patient-reported outcomes among individuals attending multidisciplinary pain treatment clinics
Angarita-Fonseca A., Lacasse A., Choinière M., Kaboré J.-L., Sylvestre M.-P., Dinkou G.D.T., Bruneau J., Martel M.O., Hovey R., Motulsky A., Rahme E., Pagé M.G., Pharmacoepidemiology and Drug Safety, 2024
Trajectories of opioid consumption as predictors of patient-reported outcomes among individuals attending multidisciplinary pain treatment clinics
Angarita-Fonseca A, Lacasse A, Choinière M, Kaboré JL, Sylvestre MP, Dinkou GDT, Bruneau J, Martel MO, Hovey R, Motulsky A, Rahme E, Pagé MG, Drug Saf. 2024
Low-dose Initiation of Buprenorphine/naloxone for the Management of Chronic Non-cancer Pain in Patients on Long-term Opioid Therapy: A Case Series
Rattanavong M, Kwan D, Jorgenson D, Landry E, Marwah R, Halpape K., Can J Pain., 2024
Author Reply to Letter to the Editor in Response to “Fentanyl Concentration in Drug Checking Samples and Risk of Overdose Death in Vancouver, Canada”
Kennedy MC, Tobias S, Dong H, Buxton JA, Lysyshyn M, Tupper KW, Ti L., Am J Prev Med. 2024
An emergency-department-initiated outreach program for patients with opioid use disorder is associated with an increase in agonist therapy and engagement in addictions care: a one-year cohort study
Lakkadghatwala R, Lane D, Scheuermeyer F, Hilburt J, Buxton J, Johnson C, Nolan S, Sutherland C, Moe J, Daoust R, Dong K, Christenson J, Miles I, Orkin A, Whyte M, Kestler A., Subst Abuse Treat Prev Policy., 2024
An emergency-department-initiated outreach program for patients with opioid use disorder is associated with an increase in agonist therapy and engagement in addictions care: a one-year cohort study
Lakkadghatwala R, Lane D, Scheuermeyer F, Hilburt J, Buxton J, Johnson C, Nolan S, Sutherland C, Moe J, Daoust R, Dong K, Christenson J, Miles I, Orkin A, Whyte M, Kestler A., Subst Abuse Treat Prev Policy. 2024
“The machine doesn’t judge”: Counternarratives on surveillance among people accessing a safer opioid supply via biometric machines
Bardwell G, Ivsins A, Wallace JR, Mansoor M, Kerr T., Soc Sci Med. 2024
Take-Home Naloxone Access and Use among Older Adults Living with Pain: A Scoping Review
Chan RRD, Yakiwchuk EM, Halpape K., Can J Hosp Pharm., 2024
Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada
Dubois C, Fernandes H, Lin M, Martins KJB, Dyck JRB, Klarenbach SW, Richer L, Jess E, Hanlon JG, Hyshka E, Eurich DT., BMC Public Health., 2024
The need for an expanded, evidence-based public health response to the overdose crisis and the toxic drug supply in Canada
Hyshka, E., Moore, D.M., Knight, R. et al., Can J Public Health, 2024
Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan
Nguyen T, Bareham J, Halpape K., Canadian Family Physician, 2024
Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis
Levinsson A, Zolopa C, Vakili F, Udhesister S, Kronfli N, Maheu-Giroux M, Bruneau J, Valerio H, Bajis S, Read P, Martró E, Boucher L, Morris L, Grebely J, Artenie A, Stone J, Vickerman P, Larney S., EClinicalMedicine, 2024
The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study
Langlois J, Nolan S, Dickhout P, Cui Z, Paterson J, Fairbairn N, Socías ME., Subst Use Addctn J. 2024
Bénéfices d’un partenariat pour l’évaluation d’un programme de prévention des surdoses initié par des pairs
Perreault M., Tremblay G., Milton D., Power N., Kucyk C., Perron-Trudel N., Santé Publique, 2024
Capacity, Rationality, and the Promotion of Autonomy: A Trauma-Informed Approach to Refusals of Care After Opioid Poisoning
Cattell C, Hyshka E, Leier B, Mack C., Am J Bioeth., 2024
A Prospective Cohort Study of Acute Pain and In-Hospital Opioid Consumption After Cardiac Surgery: Associations With Psychological and Medical Factors and Chronic Postsurgical Pain
Pagé M.G., Ganty P., Wong D., Rao V., Khan J., Ladha K., Hanlon J., Miles S., Katznelson R., Wijeysundera D., Katz J., Clarke H., Anesthesia & Analgesia, 2024
Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review
Englander H, Thakrar AP, Bagley SM, Rolley T, Dong K, Hyshka E. , JAMA Intern Med., 2024
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription‑Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
Bastien G., Abboud A., McAnulty C., Elkrief L., Ledjiar O., Socias M.E., Le Foll B., Bahji A., Brissette S., Marsan S., Jutras‑Aswad D., Journal of Dual Diagnosis, 2024
Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial
Socias ME, Cui Z, Le Foll B, Lei J, Stewart S, Anand R, Jutras-Aswad D. HIV Med. 2024
The current state of knowledge on care for co-occurring chronic pain and opioid use disorder: a scoping review
Archambault L., Bertrand K., Martel M.-O., Bérubé M., Belhouari S., Perreault M., Journal of Clinical Nursing, 2024
The effect of Montreal’s supervised consumption sites on injection-related infections among people who inject drugs: An interrupted time series
Lim J., Panagiotoglou D., PLoS ONE, 2024
Correction: Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach
Lim J., Russell W.A., El-Sheikh M., Buckeridge D.L., Panagiotoglou D., Harm Reduction Journal, 2024
Trends in toxicological findings in unintentional opioid or stimulant toxicity deaths in Québec, Canada, 2012–2021: has Québec entered a new era of drug-related deaths?
Do U., Perron P.-A., Bruneau J., Larney S., Drug and Alcohol Review, 2024
A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada
Norton A, Ivsins A, Holliday E, Sutherland C, Kerr T, Kennedy MC., Int J Drug Policy. 2024
Preferred pharmaceutical-grade opioids to reduce the use of unregulated opioids: A cross-sectional analysis among people who use unregulated opioids in Vancouver, Canada
Speed KA, Choi J, Felicella G, Sedgemore KO, Mok WY, Milloy MJ, DeBeck K, Kerr T, Hayashi K., Int J Drug Policy. 2024
Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada
Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Lim R, Socías ME., Am J Addict. 2024
What Psychiatrists Should Know About Prescribed Safer Opioid Supply
Bahji A, Danilewitz M, Sachdev A, Mathew N, Lamba W, Rafizadeh R, Chopra N, Dhaliwal A, George TP, Crockford D, Primeau V, Tibbo P, Buckley L, Tanguay R., Can J Psychiatry., 2024
Safer supply and political interference in medical practice: Alberta’s Narcotics Transition Services
Wilson P, Colizza K, Hyshka E., Int J Drug Policy., 2024
Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Lim R, Socías ME., Drug Alcohol Rev. 2024
Examining the association between fentanyl use and perceived adequacy of methadone dose: a retrospective cohort study
Young S, Raboud J, Dodd Z, DeBeck K, Milloy MJ, Wilson D, Hayashi K, Bayoumi AM, Fairbairn N, Drug Alcohol Depend
Barriers and facilitators to accessing opioid agonist therapy for street-involved adolescents and young adults in Vancouver
Gallant K, Nijjar P, DeBeck K, Cui M, Kerr T, J Addict Med
Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study
Bouthillier A, Bastien G, McAnulty C, Bakouni H, Le Foll B, Socias ME, Jutras-Aswad D., Harm Reduct J. 2025
Cannabis use and illicit opioid cessation among people who use drugs living with chronic pain
Kitchen C, Socías ME, Sayre EC, Hayashi K, DeBeck K, Milloy MJ, Kerr T, Reddon H, Drug Alcohol Rev
Experiences of Healthcare Professionals Working in Injectable Opioid Agonist Treatment Programs: A Qualitative Thematic Analysis
Gadimova, F; Jackson, J., Journal of Addictions Nursing
Illicit drug toxicity from opioid, stimulant or sedative use in adolescents: results of a Canadian one‑time cross‑sectional study
Matthew Carwana, Eva Moore, Helia Shariati, Hasina Samji, Nicholas Chadi, Paediatrics & Child Health, 2025
Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder
Anand R, Penta S, Cui Z, Fairbairn N, Socias ME., Subst Use Addctn J. 2025
Differences in overdose rates by gender at supervised consumption services: an explanatory sequential mixed methods study
Muel, E., Fan, E., Ginn, C., & Jackson, J., Drugs: Education, Prevention and Policy
Early experiences and impacts of a fentanyl powder safer supply program in Vancouver, Canada: a qualitative study
Ivsins A, Sutherland C, Kerr T, Kennedy MC., Am J Drug Alcohol Abuse. 2025
The effects of a provincial opioid prescribing standard on prescribing for pain in adults: an interrupted time‑series analysis
Dimitra Panagiotoglou, Sandra Peterson, M. Ruth Lavergne, Tara Gomes, Rashmi Chadha, Philippa Hawley, Rita McCracken, Canadian Medical Association Journal (CMAJ), 2025
Role of Pharmacists in Addiction Medicine in Canada’s Publicly Funded Health Care Systems: A Qualitative Study
Weibe, A., Pecson, R., Coupland, M., Halpape, K., Can J Hospital Pharm.
Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts Involved
Nanor Minoyan, Stine Bordier Høj, Didier Jutras‑Aswad, Sarah Larney, Valérie Martel‑Laferrière, Marie‑Pierre Sylvestre, Julie Bruneau, International Journal of Mental Health and Addiction, 2025
Evaluation of a hospital-based opioid stewardship program on high-risk opioid prescribing in a Canadian setting: an interrupted time series analysis
Ti L, Mihic T, Beauchesne A, Grant C, Frank I, Haji N, Legal M, Shalansky S, Nolan S., Addict Sci Clin Pract. 2025
Examining opioid agonist treatment (OAT) site operations and early signals of change in the first year of British Columbia’s drug decriminalization policy: Insights from a provincial survey
Russell,C., Law, J., Hodgson, K., Mackinnon, L., Shahin, R., Crichlow, F., Patenaude, S., Imtiaz, S., Rhem, J., Ali, F., Canadian Journal of Public Health
Novel adulterants in unregulated opioids and their associations with adverse events
Tobias S, Angelucci J, Wood E, Buxton JA, Ti L., Can J Public Health. 2025
Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case‑control study
Dimitra Panagiotoglou, Sandra Peterson, M. Ruth Lavergne, Tara Gomes, Rashmi Chadha, Cheyenne Johnson, Rita McCracken, Harm Reduction Journal, 2025
Intravenous Fentanyl for Symptom Management in Hospitalized Patients With Refractory Opioid Withdrawal: A Retrospective Cohort Study
Zazoulina J, Nolan S, Fairbairn N, Ryan A, Dennis BB, Bach P., J Addict Med. 2025
Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada
Mayer S, Fairbairn N, Fowler A, Boyd J, Kerr T, McNeil R., Harm Reduct J. 2025
